Rhythm Pharmaceuticals Inc To Host Virtual Bardet-Biedl Syndrome (BBS) Event Call Transcript
Welcome all, and thank you for joining us today for this virtual event on Bardet-Biedl syndrome. I'm David Meeker, Chairman, President, and Chief Executive Officer of Rhythm Pharmaceuticals. Before we get started, we want to alert you that we will be making forward-looking statements, which represent our views only as of today, and I encourage you to review this statement in our SEC filings, which are available on our website.
So this is a really exciting moment for us as we prepare to launch IMCIVREE in the United States for patients with Bardet-Biedl syndrome pending, of course, FDA approval. This will be by far our most significant milestone to date as we work to develop IMCIVREE or setmelanotide for a number of genetic and nongenetically-driven defects in the melanocortin pathway.
We're extremely fortunate to have 3 wonderful guest speakers with us today: Mary Morris, Mary and her husband are parents to 6 children, including Ashley, who is 28 and Carly who is 21, both of whom are diagnosed and living with
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
